NGAL as a Biomarker for Acute Pyelonephritis in Children: A New Tool for an Old Challenge
Introduction
Every year, urinary tract infections send millions of children to pediatric clinics and emergency departments worldwide. Most are straightforward lower tract infections — cystitis — that resolve quickly with oral antibiotics and leave no lasting damage. But a significant subset involve the kidneys themselves: acute pyelonephritis (APN), an ascending bacterial infection of the renal parenchyma that, if missed or undertreated, can scar the developing kidney and permanently impair its function.
The fundamental clinical challenge is distinguishing pyelonephritis from cystitis in children — a distinction that dictates treatment intensity, duration, follow-up imaging, and long-term surveillance. Current diagnostic tools are imperfect: urine culture takes 24–48 hours, inflammatory markers like CRP and procalcitonin lack specificity, and the gold standard imaging test — DMSA renal scintigraphy — is expensive, involves radiation, and is not available in many settings.
Neutrophil gelatinase-associated lipocalin (NGAL) has emerged as a promising candidate to fill this diagnostic gap — a novel urinary biomarker that reflects direct renal tubular injury with remarkable speed and sensitivity.
Understanding NGAL: What It Is and Where It Comes From
The Biology of NGAL
NGAL is a secretory protein of neutrophils that can be found both in plasma and urine, and previous works have demonstrated it to be a valuable marker for the early detection of acute kidney injury.
More specifically, NGAL (also known as lipocalin-2 or human neutrophil lipocalin) is a 25-kDa protein belonging to the lipocalin superfamily — a group of proteins that transport small hydrophobic molecules. In the kidney, NGAL is produced primarily by the thick ascending limb of the loop of Henle and the collecting duct tubular epithelial cells in response to injury or infection.
Key biological properties that make NGAL attractive as a biomarker:
- Rapid release: NGAL is detectable in urine within 2–4 hours of renal tubular injury — far faster than traditional markers like creatinine, which reflect GFR changes that lag hours to days behind the injury
- Stability: NGAL is resistant to proteolytic degradation in urine, making it measurable even in samples stored at room temperature for several hours
- Dual source: NGAL in urine originates from both renal tubular cells (reflecting direct tubular injury) and neutrophils infiltrating the infected tissue — both sources are activated in pyelonephritis
- Antibacterial function: NGAL plays a direct innate immune role by sequestering siderophores — iron-chelating molecules that bacteria use to acquire iron — thereby limiting bacterial growth
NGAL in the Context of Infection vs. Injury
An important nuance: NGAL is elevated in two distinct contexts:
- Acute kidney injury (AKI) — ischemic or nephrotoxic tubular damage; NGAL was first characterized as an AKI biomarker
- Urinary tract infection with renal involvement — bacterial invasion of the renal parenchyma triggers both tubular cell NGAL release and neutrophil infiltration
This dual elevation means NGAL is not specific to one pathological process, but its magnitude and clinical context guide interpretation.
The Diagnostic Problem: Why Distinguishing APN From Cystitis Matters
Consequences of Misdiagnosis
In children, the consequences of missing acute pyelonephritis — or of over-treating cystitis as APN — are both significant:
Under-treatment of APN:
- Inadequate antibiotic duration and route → treatment failure
- Untreated renal parenchymal infection → renal scarring
- Renal scarring in children leads to: hypertension (develops in ~10–20% of children with significant scars), impaired renal growth, proteinuria, and — in severe bilateral scarring — chronic kidney disease
Over-treatment of cystitis as APN:
- Unnecessary intravenous antibiotics
- Prolonged hospitalization
- Unnecessary DMSA scintigraphy (radiation exposure)
- Healthcare resource misallocation
The clinical stakes are highest in infants and young children under 2 years — who have the highest risk of renal scarring from pyelonephritis, are least able to articulate symptoms, and are most difficult to evaluate with standard criteria.
Limitations of Current Diagnostic Tools
| Diagnostic Tool | Advantage | Limitation |
| Urine culture | Gold standard for UTI confirmation | 24–48 hour delay; can’t distinguish upper from lower tract |
| Urinalysis (pyuria, nitrites) | Rapid, inexpensive | Low specificity; negative does not exclude APN |
| CRP (C-reactive protein) | Widely available | Rises 24–48 hours after infection onset; not kidney-specific |
| Procalcitonin (PCT) | Better APN predictor than CRP | Cost; availability in many settings |
| DMSA renal scintigraphy | Gold standard for parenchymal involvement | Radiation; cost; requires nuclear medicine facility; 3–6 months for scarring assessment |
| Renal ultrasound | Non-invasive | Insensitive for early APN; misses most cases |
| Urine NGAL | Rapid; non-invasive; kidney-specific | Requires ELISA; less widely available than standard labs |
The Evidence: NGAL in Pediatric APN
The Kurdistan University Study
The aim of the study was to assess whether urine NGAL could represent a reliable biomarker for diagnosis and treatment of children with acute pyelonephritis. A total of 37 children (32 females, 5 males) with APN were included in this prospective study. Urine NGAL was measured before and 5–7 days after antibiotic treatment in the UTI group, using ELISA kit and compared with 26 (8 females, 18 males) control group children admitted for other bacterial infections.
The conclusion was that urine NGAL is a good biomarker for diagnosis and treatment monitoring of APN in children.
This dual finding — diagnostic utility and treatment monitoring value — is particularly important: NGAL not only identifies APN at presentation but tracks the resolution of renal inflammation during antibiotic therapy, providing an objective measure of treatment response.
What Other Studies Show
The broader literature on NGAL in pediatric UTI and APN presents a nuanced but generally supportive picture:
In one prospective study enrolling 60 patients with symptomatic UTI and 29 healthy controls, mean urine NGAL level was significantly higher in the UTI group than in controls (91.02 ng/mL vs 14.29 ng/mL, p = 0.0001), and using a cutoff of 20 ng/mL for urine NGAL, sensitivity and specificity for UTI diagnosis were 97% and 76%, respectively (AUC: 0.979).
In adult pyelonephritis, median urine NGAL levels at infection diagnosis were significantly higher in the pyelonephritis group than the non-pyelonephritis group (302 ng/mL vs 25 ng/mL, p = 0.006), with no differences between the two groups at days 3 and 7 of treatment.
The rapid fall of NGAL with treatment mirrors the clinical course of APN — making it a real-time treatment monitor, not just a static diagnostic snapshot.
Where NGAL Performs Less Well
Not all studies are uniformly positive. Some important nuances:
One prospective study of children aged 1–24 months with febrile UTI found no significant differences in normalized or non-normalized values of urine NGAL between children with APN and those with lower UTI, suggesting limited ability to distinguish upper from lower tract infection in this specific age group.
A large screening study of 812 urine specimens concluded it may not be appropriate to use NGAL as a marker for early diagnosis of UTI in children, noting that NGAL values were more elevated in UTI cases but the difference between UTI and non-UTI cases was not statistically significant.
These discordant findings likely reflect differences in:
- Patient age and developmental stage
- Cutoff values used
- NGAL measurement method (urine vs. plasma; ELISA vs. point-of-care)
- Reference standard used (DMSA vs. clinical criteria)
- Degree of renal involvement in the study population
NGAL Beyond APN: Broader Urological Applications in Children
Vesicoureteral Reflux and Renal Scarring
A study evaluating urine NGAL in children with primary vesicoureteral reflux found that mean urine NGAL and urine NGAL/creatinine ratio were significantly higher in patients with VUR (p = 0.012 and p = 0.003, respectively), and urine NGAL/creatinine increased significantly in patients with decreased parenchymal function compared to those with normal DMSA scans.
This extends NGAL’s potential role — not just as an APN diagnostic tool, but as a non-invasive surrogate for renal parenchymal damage in children with chronic conditions like VUR.
Monitoring Treatment Response
One of NGAL’s most clinically compelling applications is treatment monitoring — tracking whether antibiotic therapy is adequately resolving renal infection. Traditional markers (CRP, white cell count) normalize slowly and non-specifically. NGAL, reflecting active tubular injury, normalizes as the infection resolves — potentially guiding decisions about antibiotic duration, route switching (IV to oral), and timing of follow-up imaging.
Practical Considerations: Implementing NGAL in Clinical Practice
How NGAL Is Measured
Currently, urine NGAL measurement requires:
- ELISA (enzyme-linked immunosorbent assay): most commonly used in research; highly sensitive and quantitative; requires laboratory infrastructure and 2–4 hours processing time
- Point-of-care immunoassay (ARCHITECT platform, Triage NGAL): faster (< 30 minutes); being validated in clinical settings; not universally available
- Urine NGAL/creatinine ratio: normalizing NGAL to urine creatinine corrects for urine concentration variability — important in children where dilution varies significantly
Key Diagnostic Thresholds
| Cutoff Value | Sensitivity | Specificity | Clinical Context |
| > 20 ng/mL (uNGAL) | ~97% | ~76% | UTI vs. no UTI (Yilmaz et al.) |
| > 100 ng/mL (uNGAL) | ~85% | ~90% | APN vs. lower UTI (varied studies) |
| Elevated uNGAL/Cr ratio | Variable | Variable | VUR with parenchymal damage |
| Normalization after 5–7 days | Treatment response marker | — | APN treatment monitoring |
Optimal cutoff values remain study-dependent — highlighting the need for larger prospective validation studies before universal clinical thresholds can be standardized.
NGAL in a Diagnostic Panel
Rather than replacing existing tests, NGAL is best understood as an additive biomarker within a diagnostic panel:
- Urinalysis + urine culture: establishes UTI diagnosis and identifies pathogen
- CRP or procalcitonin: systemic inflammatory response assessment
- Urine NGAL: renal parenchymal involvement — adds specificity for upper tract disease
- DMSA scintigraphy: reserved for cases where NGAL and other markers are discordant, or for definitive scarring assessment at 3–6 months
Conclusion
Acute pyelonephritis in children demands accurate, rapid diagnosis — and the available evidence positions urine NGAL as a valuable addition to the pediatric urologist’s and nephrologist’s diagnostic toolkit. The Kurdistan University of Medical Sciences study, alongside a growing body of international literature, confirms that urine NGAL is elevated in children with APN, correlates with renal parenchymal injury, and falls with successful antibiotic treatment — making it both a diagnostic and a treatment monitoring biomarker.
The technology is not yet universally standardized, optimal cutoffs require further validation across age groups, and point-of-care platforms need wider deployment before routine clinical adoption. But the biological rationale is sound, the early clinical evidence is promising, and the unmet need — rapid, non-invasive identification of upper urinary tract infection in children — is genuine and consequential.
Your next steps if your child has been diagnosed with a urinary tract infection:
- Ask whether the infection has been assessed as cystitis (lower tract) or pyelonephritis (upper tract) — the distinction determines treatment duration, route, and follow-up
- Understand that DMSA scintigraphy, while the gold standard for renal scarring assessment, is not always necessary in first febrile UTI — ask your pediatric urologist or nephrologist whether imaging is indicated for your child’s specific situation
- Inquire whether urine NGAL or procalcitonin testing is available at your center as part of APN risk stratification
- Ensure any child with confirmed APN has follow-up renal ultrasound and assessment for vesicoureteral reflux — both conditions that warrant long-term surveillance
- For children with recurrent UTIs, ask about NGAL/creatinine ratio monitoring as a non-invasive tool for detecting ongoing renal parenchymal stress